|
Number of patients (%)
|
1309
|
819 (63)a
|
490 (37)a
| |
|
Age baseline, years
|
42 (38–46)
|
42 (38–46)
|
42 (37–46)
|
0.04
|
|
Baseline BMI
| | | |
<0.0001
|
|
< 25
|
329 (25b)
|
234 (71)
|
95 (29)
| |
|
> =25
|
123 (9)
|
96 (78)
|
27 (22)
| |
|
Unknown
|
857 (66)
|
489 (57)
|
368 (43)
| |
|
Gender
| | | |
0.57
|
|
Male
|
960 (73)
|
605 (63)
|
355 (37)
| |
|
Female
|
349 (39)
|
214 (61)
|
135 (39)
| |
|
HIV transmission route:
| | | |
0.05
|
|
Men who have sex with men
|
175 (13)
|
91 (52)
|
84 (48)
| |
|
Male, injection drug use (IDU)
|
595 (45)
|
393 (66)
|
202 (34)
| |
|
Female IDU
|
209 (16)
|
127 (61)
|
82 (39)
| |
|
Male heterosexual
|
84 (6)
|
55 (65)
|
29 (35)
| |
|
Female heterosexual
|
96 (7)
|
62 (65)
|
34 (35)
| |
|
Male other/unknown
|
106 (8)
|
66 (62)
|
40 (38)
| |
|
Female other/unknown
|
44 (3)
|
25 (57)
|
19 (43)
| |
|
Region of origin:
| | | |
0.06
|
|
Western
|
1101 (84)
|
700 (64)
|
401 (36)
| |
|
Other
|
116 (9)
|
72 (62)
|
44 (38)
| |
|
Unknown
|
92 (7)
|
47 (51)
|
45 (49)
| |
|
CD4 at baseline (cells/μl)
| | | | |
|
0–349
|
264 (20)
|
163 (62)
|
101 (38)
|
0.02
|
|
350–499
|
306 (23)
|
194 (63)
|
112 (37)
| |
|
> =500
|
491 (38)
|
288 (59)
|
203 (41)
| |
|
Missing
|
248 (19)
|
174 (70)
|
74 (30)
| |
|
Nadir CD4 (cells/ μl)
| | | |
<0.001
|
|
< 200
|
689 (53)
|
434 (63)
|
255 (37)
| |
|
> =200
|
583 (45)
|
381 (65)
|
202 (35)
| |
|
Missing
|
37 (3)
|
4 (11)
|
33 (89)
| |
|
HIV RNA levels at baseline (copies/ml)
| | | |
0.99
|
|
< =400
|
1082 (83)
|
677 (63)
|
405 (37)
| |
|
> 400
|
227 (17)
|
142 (63)
|
85 (37)
| |
|
Hepatitis B virus co-infection
| | | |
0.64
|
|
No
|
1214 (93)
|
762 (63)
|
452 (37)
| |
|
Yes
|
53 (4)
|
30 (57)
|
23 (43)
| |
|
Unknown
|
42 (3)
|
27 (64)
|
14 (33)
| |
|
HCV RNA load at baseline
| | | |
<0.0001
|
|
< 600,000
|
222 (17)
|
99 (45)
|
123 (55)
| |
|
≥ 600,000
|
724 (55)
|
485 (67)
|
239 (33)
| |
|
Missing
|
363 (28)
|
235 (65)
|
128 (35)
| |
|
HCV genotypes
| | | |
<0.0001
|
|
1
|
82 (6)
|
53 (65)
|
29 (35)
| |
|
1a
|
307 (23)
|
234 (76)
|
83 (27)
| |
|
1b
|
147 (11)
|
108 (73)
|
39 (27)
| |
|
2&3
|
315 (24)
|
154 (49)
|
161 (51)
| |
|
4
|
143 (11)
|
103 (72)
|
40 (28)
| |
|
Other/unknown
|
315 (24)
|
177 (56)
|
138 (44)
| |
|
APRIc score:
| | | |
<0.0001
|
|
< 0.5
|
409 (31)
|
206 (50)
|
203 (50)
| |
|
0.5–1.5
|
426 (32)
|
312 (73)
|
114 (27)
| |
|
> =1.5
|
195 (15)
|
155 (79)
|
40 (21)
| |
|
Unknown
|
279 (21)
|
146 (52)
|
133 (48)
| |
|
Decline in haemoglobin (g/dl)
| | | |
0.0017
|
|
No decline
|
179 (14)
|
126 (70)
|
53 (30)
| |
|
< =2.5
|
227 (17)
|
157 (69)
|
70 (31)
| |
|
> 2.5
|
230 (18)
|
127 (55)
|
103 (45)
| |
|
Missing
|
637 (49)
|
409 (64)
|
264 (41)
| |
|
Duration of HCV treatment in weeks
| | | |
<0.0001
|
|
< =24
|
496 (38)
|
390 (79)
|
106 (21)
| |
|
24-48
|
437 (33)
|
242 (55)
|
195 (45)
| |
|
> 48
|
376 (29)
|
187 (50)
|
189 (50)
| |
|
Calendar year of start HCV treatment
| | | |
<0.0001
|
|
< =2003
|
266 (20)
|
201 (76)
|
65(24)
| |
|
2003–2006
|
421 (32)
|
258 (61)
|
163 (39)
| |
|
> =2006
|
622 (48)
|
360 (58)
|
262 (42)
| |
|
cART regimen
| | | |
0.003
|
|
PI
|
158 (12)
|
104 (66)
|
54 (34)
| |
|
Boosted PI
|
444 (34)
|
296 (67)
|
148 (33)
| |
|
NNRTI
|
284 (22)
|
154 (54)
|
130 (46)
| |
|
PI + NNRTI
|
50 (6)
|
35 (70)
|
15 (30)
| |
|
No PI and/or NNRTI
|
131 (10)
|
90 (69)
|
41 (31)
| |
|
no cART
|
242 (18)
|
140 (58)
|
102 (42)
| |
|
Backbone
| | | |
<0.0001
|
|
Start after HCV treatment
|
242 (18)
|
140 (58)
|
102 (42)
| |
|
ABC + 3TC
|
189 (14)
|
117 (62)
|
72 (38)
| |
|
AZT + 3TC
|
140 (11)
|
99 (62)
|
41 (29)
| |
|
FTC + TDF
|
262 (20)
|
147 (56)
|
115 (44)
| |
|
TDF + 3TC
|
130 (10)
|
68 (52)
|
62 (48)
| |
|
TDF + ABC
|
44 (3)
|
27 (61)
|
17 (39)
| |
|
d4T + 3TC
|
90 (7)
|
68 (76)
|
22 (24)
| |
|
other
|
212 (16)
|
153 (72)
|
59 (28)
| |
